Cargando…

Consequences of a high incidence of microsatellite instability and BRAF‐mutated tumors: A population‐based cohort of metastatic colorectal cancer patients

BACKGROUND: Immunotherapy for patients with microsatellite‐instable (MSI‐H) tumors or BRAF‐inhibitors combination treatment for BRAF‐mutated (mutBRAF) tumors in metastatic colorectal cancer (mCRC) is promising, but the frequency of these molecular changes in trial patients are low. Unselected popula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aasebø, Kristine Ø., Dragomir, Anca, Sundström, Magnus, Mezheyeuski, Artur, Edqvist, Per‐Henrik, Eide, Geir Egil, Ponten, Fredrik, Pfeiffer, Per, Glimelius, Bengt, Sorbye, Halfdan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Cancer Prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601706/ https://www.ncbi.nlm.nih.gov/pubmed/31070306 http://dx.doi.org/10.1002/cam4.2205

Ejemplares similares

CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup
por: Aasebø, Kristine, et al.
Publicado: (2020)

High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort
por: Sorbye, Halfdan, et al.
Publicado: (2015)

High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer
por: Siesing, Christina, et al.
Publicado: (2017)

Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer
por: Mezheyeuski, Artur, et al.
Publicado: (2016)

Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer
por: Birgisson, Helgi, et al.
Publicado: (2015)

The Immune Landscape of Colorectal Cancer
por: Mezheyeuski, Artur, et al.
Publicado: (2021)

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9
por: Winther, Stine Braendegaard, et al.
Publicado: (2017)

Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer
por: Mezheyeuski, Artur, et al.
Publicado: (2017)

Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients
por: Niinivirta, Marjut, et al.
Publicado: (2017)

Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib
por: Niinivirta, Marjut, et al.
Publicado: (2017)

Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome
por: Thomsen, Maria, et al.
Publicado: (2018)

Population bias in somatic measurement of microsatellite instability status
por: Saul, Michelle, et al.
Publicado: (2020)

Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases
por: Angelsen, Jon-Helge, et al.
Publicado: (2015)

Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study
por: Tarpgaard, Line S., et al.
Publicado: (2014)

Chromosomal Instability in BRAF Mutant, Microsatellite Stable Colorectal Cancers
por: Bond, Catherine E., et al.
Publicado: (2012)

Let-7 miRNA-binding site polymorphism in the KRAS 3(′)UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/− cetuximab
por: Kjersem, Janne B, et al.
Publicado: (2012)

Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer
por: Thomsen, Maria, et al.
Publicado: (2016)

Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases
por: Løes, Inger Marie, et al.
Publicado: (2016)

Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer
por: Seppälä, T T, et al.
Publicado: (2015)

Prognostic value of the combination of microsatellite instability and BRAF mutation in colorectal cancer
por: Yang, Yingchi, et al.
Publicado: (2018)

Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients
por: Larsen, S. G., et al.
Publicado: (2021)

KRAS, NRAS, BRAF, HER2 and Microsatellite Instability in Metastatic Colorectal Cancer – Practical Implications for the Clinician
por: Afrăsânie, Vlad-Adrian, et al.
Publicado: (2019)

Microsatellite instability in sporadic colorectal cancer is not an independent prognostic factor
por: Salahshor, S, et al.
Publicado: (1999)

Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study
por: Guren, Tormod Kyrre, et al.
Publicado: (2017)

Stroma-normalised vessel density predicts benefit from adjuvant fluorouracil-based chemotherapy in patients with stage II/III colon cancer
por: Mezheyeuski, Artur, et al.
Publicado: (2019)

Mindfulness and its efficacy for psychological and biological responses in women with breast cancer
por: Kenne Sarenmalm, Elisabeth, et al.
Publicado: (2017)

The Prognostic Value of Pre-Treatment Circulating Biomarkers of Systemic Inflammation (CRP, dNLR, YKL-40, and IL-6) in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study
por: Liposits, Gabor, et al.
Publicado: (2022)

Beyond the NCCN Risk Factors in Colon Cancer: An Evaluation in a Swedish Population-Based Cohort
por: Osterman, Erik, et al.
Publicado: (2020)

Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy—The Randomized NORDIC9-Study
por: Liposits, Gabor, et al.
Publicado: (2021)

The role of autophagy in the treatment of BRAF mutant colorectal carcinomas differs based on microsatellite instability status
por: Koustas, Evangelos, et al.
Publicado: (2018)

Editorial: Microsatellite and microsatellite instability
por: How-Kit, Alexandre, et al.
Publicado: (2023)

BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status
por: Jang, Min Hye, et al.
Publicado: (2017)

Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study
por: Brim, Hassan, et al.
Publicado: (2008)

CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer
por: Wu, Christina, et al.
Publicado: (2012)

External validation of molecular subtype classifications of colorectal cancer based on microsatellite instability, CIMP, BRAF and KRAS
por: Alwers, Elizabeth, et al.
Publicado: (2019)

An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers
por: Mezheyeuski, Artur, et al.
Publicado: (2023)

Barriers and facilitators to participation in a health check for cardiometabolic diseases in primary care: A systematic review
por: de Waard, Anne-Karien M, et al.
Publicado: (2018)

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer
por: Osterlund, Emerik, et al.
Publicado: (2022)

TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer
por: Tarpgaard, Line S., et al.
Publicado: (2016)

BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status
por: Qi Li, Wei, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_ctfr5fk13a49q9kook7l6agsal